XTLB XTL Biopharmaceuticals Ltd

REHOVOT, Israel, November 3 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd ("XTLbio") (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL) today announced that Ram Waisbourd, Vice President, Business Development, will present an overview of the Company at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference in New York City. Mr. Waisbourd's presentation will take place on Monday, 7 November 2005 at 8:10 pm UK time (3:10 pm EST) in the Adams Room at the New York Palace Hotel. A live audio webcast of Mr. Waisbourd's presentation will be available during the presentation at http://www.wsw.com/webcast/rrshq7/xtlb/ and will be archived for a period of 90 days, beginning approximately 3 hours following the conclusion of the live presentation. Contacts: XTLbio Jonathan Burgin, Chief Financial Officer Tel: +972-8-930-4440 About XTL Biopharmaceuticals Ltd. Established in 1993, XTL Biopharmaceuticals Ltd. (LSE:XTL)(NASDAQ:XTLB) ( TASE: XTL) is a biopharmaceutical company engaged in the acquisition, development and commercialization of pharmaceutical products for the treatment of infectious diseases, particularly the prevention and treatment of hepatitis B and C. Cautionary Statement Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the US Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially, and therefore affect interest by investors in our securities, are the following: the results of prior trails with XTL-686are not necessarily indicative of the results we may have in the Phase 1a and 1b trials; and other risk factors identified from time to time in our reports filed with the various regulatory bodies. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.xtlbio.com/. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only. DATASOURCE: XTL Biopharmaceuticals Ltd. CONTACT: Contacts: XTLbio: Jonathan Burgin, Chief Financial Officer, Tel: +972-8-930-4440

Copyright